WHO recommendations on shorter treatment of multidrug-resistant tuberculosis

This publication has 9 references indexed in Scilit:

• Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
  The Lancet Infectious Diseases, 2016
• Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
  The Lancet Infectious Diseases, 2016
• Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics
  European Respiratory Journal, 2016
• Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
  European Respiratory Journal, 2016
• Classification of antituberculosis drugs: a new proposal based on the most recent evidence
  European Respiratory Journal, 2015
• Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients
  The International Journal of Tuberculosis and Lung Disease, 2014
• High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses
  The International Journal of Tuberculosis and Lung Disease, 2014
• Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis
  European Respiratory Journal, 2012
• Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
  American Journal of Respiratory and Critical Care Medicine, 2010